Status:
COMPLETED
Resilience and Coping in a Rare Skeletal Disease Population to Face Coronavirus (COVID-19) Outbreak Distress: a Longitudinal Study
Lead Sponsor:
Istituto Ortopedico Rizzoli
Conditions:
Multiple Osteochondroma
Osteogenesis Imperfecta
Eligibility:
All Genders
8-24 years
Brief Summary
In the COVID-19 outbreak context, people living with rare diseases have been highly troubled with anxiety, loneliness, and depression. The project evaluates resilience and coping strategies to address...
Detailed Description
March 11th, 2020, the World Health Organization (WHO) declared the SARS-CoV-2 pandemic accordingly with the spread and size of the infection. The restrictions implemented by the governments have subs...
Eligibility Criteria
Inclusion
- Clinical and/or molecular diagnosis of Multiple osteochondromas; Clinical and/or molecular diagnosis of Ollier disease/Maffucci syndrome; Clinical and/or molecular diagnosis of Osteogenesis imperfecta; Consent to participate in the study
Exclusion
- Subject doesn't match the inclusion criteria
Key Trial Info
Start Date :
May 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04844697
Start Date
May 12 2021
End Date
December 31 2022
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy, 40139